Ignite Creation Date:
2024-05-06 @ 8:54 AM
Last Modification Date:
2024-10-26 @ 12:07 PM
Study NCT ID:
NCT02853071
Status:
WITHDRAWN
Last Update Posted:
2019-11-18
First Post:
2016-07-29
Brief Title:
Efficacy and Safety of Estracyt in Metastatic Breast Cancer
Sponsor:
Centre Hospitalier Universitaire de Besancon
Organization:
Centre Hospitalier Universitaire de Besancon
Study Overview
Official Title:
Efficacy and Safety of Estracyt in Metastatic Breast Cancer Hormonal Estrogen Receptor HER 2 Negative Hormone Receptor HR Positive
Status:
WITHDRAWN
Status Verified Date:
2019-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
withdrawal industrial
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
BEST
Brief Summary:
This study evaluates efficacy safety and quality of life in patients affected by metastatic breast cancer RH HER2- and treated by estramustine phosphate
Detailed Description:
For patients affected by metastatic breast cancer RHHER2- the conventional treatment is hormonotherapy But when patients dont react no recommendations exist
Estramustine phosphate is currently prescribed for prostate cancer The estramustine phosphate is an active anti-tumoral agent by oral route associating a nitrogenous mustard with the estradiol it settles on membrane receptor and the cytotoxic component acts essentially by dismantling microtubules inhibiting the mitosis
Estramustine could be a therapeutic option when currently therapy are exhausted for patients reactive to hormonotherapy previous lines or chemotherapy
Estramustine phosphate is currently prescribed for prostate cancer The estramustine phosphate is an active anti-tumoral agent by oral route associating a nitrogenous mustard with the estradiol it settles on membrane receptor and the cytotoxic component acts essentially by dismantling microtubules inhibiting the mitosis
Estramustine could be a therapeutic option when currently therapy are exhausted for patients reactive to hormonotherapy previous lines or chemotherapy
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None